

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of:

NI *et al.*

Appl. No. 09/340,690

Filed: June 29, 1999

For: **Human Tumor Necrosis Factor
Receptor-Like 2**



Art Unit: 1646

Examiner: To be assigned

Atty. Docket: 1488.0770007/EKS/SGW

#5
JCS
10/19/99

Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents AM2, AS36 and AT36 are simultaneously being submitted to the Office in Appl. No. 08/741,095, filed October 30, 1996, which is relied upon for an earlier filing date under 35 U.S.C. § 120. While submission of copies of documents AM2, AS36, and AT36 in the captioned application is not required, they are included herewith as a courtesy to the Examiner.

Copies of the remaining documents were previously cited by or submitted to the Office in Appl. No. 08/741,095, filed October 30, 1996, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, submission of copies of these documents is not required. 37 C.F.R. § 1.98(d)

The Examiner is referred to the following list of related, co-pending patent applications:

Appl. No. 08/815,469, filed March 11, 1997;

Appl. No. 09/314,889, filed May 19, 1999; and

Appl. No. 09/333,966, filed June 16, 1999.

Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:1, 4, 7 and the corresponding clone of this application may be related to: SEQ ID NO:999 in co-pending U.S. Patent Application No. 08/104,507, filed August 9, 1993; SEQ ID NO:8615 in co-pending U.S. Patent Application No. 08/196,363, filed February 15, 1994; SEQ ID NOS:949, 11643, and 11665 in co-pending U.S. Patent Application No. 08/220,691, filed March 31, 1994; SEQ ID NOS:1846 and 204 in co-pending U.S. Patent Application No. 08/220,661, filed March 31, 1994; SEQ ID NO:296 in co-pending U.S. Patent Application No. 08/275,627, filed July 15, 1994; SEQ ID NO:1513 in co-pending U.S. Patent Application No. 08/276,163, filed July 15, 1994; SEQ ID NOS:8913, 11969, 9747, and 7031 in co-pending U.S. Patent Application No. 08/346,731, filed November 21, 1994; SEQ ID NOS:2867 and 3070 in co-pending U.S. Patent Application No. 08/790,776, filed January 30, 1997; SEQ ID NOS:4016, 2900, and 8648 in co-pending U.S. Patent Application No. 08/790,774, filed January 30, 1997; SEQ ID NO:8469 in co-pending U.S. Patent Application No. 08/798,074, filed February 12, 1997; SEQ ID NO:6416 in co-pending U.S. Patent Application No. 08/803,609, filed February 21, 1997; SEQ ID NO:8182 in co-pending U.S. Patent Application No. 08/971,197, filed November 14, 1997; SEQ ID NO:713 in co-pending U.S. Patent Application No. 08/985,356, filed December

4, 1997; and SEQ ID NO:1903 in co-pending U.S. Patent Application No. 09/076,897, filed May 13, 1998.

The identification of the U.S. Patent Applications set out herein is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Stephen G. Whiteside
Attorney for Applicants
Registration No. 42,224

Date: 9/30/99

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600